Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 105Head & Neck 12Genitourinary 12Thoracic 11Breast 9Endocrine 8Gynecologic 4Tumor-Agnostic 3Sarcoma 3Other solid neoplasm 3NET 2Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Follicular 1Breast Neoplasms 1

Interventions

Rituximab 1401Cyclophosphamide 1306Vincristine 668Doxorubicin 587Etoposide 527Prednisone 511Cytarabine 486fludarabine 470Methotrexate 445Dexamethasone 413fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 282Radiotherapy 267venetoclax 261ibrutinib 258obinutuzumab 236Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 162Magnetic Resonance Spectroscopy 155Calcium Dobesilate 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Radiofrequency Ablation × Lymphoid × Clear all
NCT07206121 2026-02-11

Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery

Innoblative Designs, Inc.

Phase NA Recruiting
10 enrolled
BreastLymphoid

Breast Neoplasms, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡